The ELF™ Test is a non-invasive blood test that can be performed on Atellica® IM Analyzer and ADVIA Centaur® Immunoassay systems. It measures three markers of fibrosis in the liver: hyaluronic acid (HA), procollagen III amino-terminal peptide (PIIINP), and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1). When used in conjunction with other laboratory and clinical findings, it can be used to assess the risk of progression to cirrhosis and liver-related clinical events (LREs) in patients with chronic liver disease.

This test is accessible to all healthcare practitioners and patients, including those with type 2 diabetes mellitus and obesity. It can help improve patient care by identifying non-alcoholic fatty liver disease (NAFLD) patients and stratifying those at risk of progressing to cirrhosis and LREs. It also has been proven to outperform traditional biopsy in the assessment of progression to cirrhosis and LREs. The performance of the ELF Test for liver fibrosis has been well-established in scientific literature and its ease of testing and interpretation support its routine clinical use as an alternative to invasive biopsy.

Facebook Page of the Solution

Twitter Page of the Solution

linkedin Page of the Solution

Website of the Solution